{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:09:11Z","timestamp":1792688951644,"version":"4.5.0"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bcp.2026.117741","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:44:04Z","timestamp":1769186644000},"page":"117741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting MRP4 in drug resistance and aspirin treatment failure: implications for precision medicine"],"prefix":"10.1016","volume":"246","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1667-4548","authenticated-orcid":false,"given":"Simone","family":"De Corci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Schiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Terracina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio M.","family":"Pulcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0968-0004(93)90080-7","article-title":"Membrane traffic wardens and protein secretion in gram-negative bacteria","volume":"18","author":"Salmond","year":"1993","journal-title":"Trends Biochem. Sci"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/mr.57.1.50-108.1993","article-title":"The complete general secretory pathway in gram-negative bacteria","volume":"57","author":"Pugsley","year":"1993","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.bcp.2026.117741_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.cb.08.110192.000435","article-title":"ABC transporters: from microorganisms to man","volume":"8","author":"Higgins","year":"1992","journal-title":"Annu. Rev. Cell Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.117741_b0020","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/hmg\/5.10.1649","article-title":"Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database","volume":"5","author":"Allikmets","year":"1996","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0025","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrm2646","article-title":"ABC transporters: the power to change","volume":"10","author":"Rees","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"Pt 2","key":"10.1016\/j.bcp.2026.117741_b0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/bj20021886","article-title":"Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4)","volume":"371","author":"Zelcer","year":"2003","journal-title":"Biochem. J"},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tips.2008.01.006","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4): a versatile efflux transporter for drugs and signalling molecules","volume":"29","author":"Russel","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0040","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0959-437X(95)80011-S","article-title":"Evolution of ATP-binding cassette transporter genes","volume":"5","author":"Dean","year":"1995","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.sbi.2007.07.003","article-title":"Structure and mechanism of ABC transporter proteins","volume":"17","author":"Hollenstein","year":"2007","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bcp.2026.117741_b0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2014.05.001","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) regulates thrombus formation in vitro and in vivo","volume":"737","author":"Lien","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0055","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2174\/0929867325666171229133259","article-title":"MRP4\/ABCC4 As a new therapeutic target: meta-analysis to determine cAMP binding sites as a tool for drug design","volume":"26","author":"Yaneff","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0060","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1074\/jbc.M110.166868","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation","volume":"286","author":"Copsel","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.117741_b0065","first-page":"343","article-title":"ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer","volume":"7","author":"Zhao","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"13","key":"10.1016\/j.bcp.2026.117741_b0070","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/pros.20809","article-title":"Androgen regulation of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in prostate cancer","volume":"68","author":"Ho","year":"2008","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.pcan.4500912","article-title":"Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells","volume":"10","author":"Cai","year":"2007","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0080","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gene.2011.09.029","article-title":"The ABCC4 gene is a promising target for pancreatic cancer therapy","volume":"491","author":"Zhang","year":"2012","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1124\/mol.118.115444","article-title":"Identification of MRP4\/ABCC4 as a target for reducing the proliferation of pancreatic ductal adenocarcinoma cells by modulating the cAMP efflux","volume":"96","author":"Carozzo","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0090","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.18632\/oncotarget.14145","article-title":"Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal\/triple negative breast cancer","volume":"8","author":"Kochel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.117741_b0095","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijbiomac.2020.06.106","article-title":"Multidrug resistance protein 4 (MRP4\/ABCC4) is overexpressed in clear cell renal cell carcinoma (ccRCC) and is essential to regulate cell proliferation","volume":"161","author":"Colavita","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.117741_b0100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/bs.acr.2014.10.005","article-title":"ABC transporters and neuroblastoma","volume":"125","author":"Yu","year":"2015","journal-title":"Adv. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/1535-7163.MCT-04-0161","article-title":"Expression of multidrug transporter MRP4\/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro","volume":"4","author":"Norris","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0110","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41416-024-02581-2","article-title":"ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling","volume":"130","author":"Chiang","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2026.117741_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.06.015","article-title":"Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics","volume":"231","author":"Berthier","year":"2019","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1681\/ASN.2005090966","article-title":"Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide","volume":"18","author":"Hasegawa","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/12487","article-title":"MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs","volume":"5","author":"Schuetz","year":"1999","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0130","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jmv.21152","article-title":"Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy","volume":"80","author":"Turriziani","year":"2008","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.106.028233","article-title":"Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir","volume":"71","author":"Imaoka","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0140","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1124\/mol.62.6.1321","article-title":"Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells","volume":"62","author":"Wielinga","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"36","key":"10.1016\/j.bcp.2026.117741_b0145","doi-asserted-by":"crossref","first-page":"33747","DOI":"10.1074\/jbc.M104833200","article-title":"Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. resistance to 6-mercaptopurine and 6-thioguanine","volume":"276","author":"Chen","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0150","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/humu.20694","article-title":"6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4","volume":"29","author":"Janke","year":"2008","journal-title":"Hum. Mutat."},{"issue":"17","key":"10.1016\/j.bcp.2026.117741_b0155","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/138920006774832550","article-title":"Topotecan is a substrate for multidrug resistance associated protein 4","volume":"7","author":"Tian","year":"2006","journal-title":"Curr. Drug Metab."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0165","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2011.03.049","article-title":"Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting","volume":"58","author":"Mattiello","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"10.1016\/j.bcp.2026.117741_b0170","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.amjmed.2006.10.021","article-title":"Aspirin resistance and adverse clinical events in patients with coronary artery disease","volume":"120","author":"Chen","year":"2007","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2026.117741_b0180","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2015.12.003","article-title":"High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI","volume":"30","author":"Gori","year":"2016","journal-title":"Eur. J. Intern. Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0185","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1160\/TH16-04-0316","article-title":"Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment","volume":"116","author":"Massimi","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0190","first-page":"3537","article-title":"Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines","volume":"57","author":"Kool","year":"1997","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0195","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.bmcl.2008.05.047","article-title":"Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4\/ABCC4)","volume":"18","author":"Ravna","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0200","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41594-023-01176-4","article-title":"Structural basis of prostaglandin efflux by MRP4","volume":"31","author":"Pourmal","year":"2024","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0205","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13578-025-01377-y","article-title":"Structural basis of human ABCC4 recognition of cAMP and ligand recognition flexibility","volume":"15","author":"Wen","year":"2025","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6976.1998.tb00358.x","article-title":"ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits\/domains","volume":"22","author":"Schneider","year":"1998","journal-title":"FEMS Microbiol. Rev."},{"issue":"6087","key":"10.1016\/j.bcp.2026.117741_b0215","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/323448a0","article-title":"A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria","volume":"323","author":"Higgins","year":"1986","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0220","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/92.16.1295","article-title":"A family of drug transporters: the multidrug resistance-associated proteins","volume":"92","author":"Borst","year":"2000","journal-title":"J. Natl Cancer Inst."},{"issue":"13","key":"10.1016\/j.bcp.2026.117741_b0225","first-page":"2741","article-title":"Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein\/canalicular multispecific organic anion transporter-related transporter","volume":"58","author":"Lee","year":"1998","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0230","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1152\/ajprenal.00133.2004","article-title":"Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites","volume":"288","author":"Van Aubel","year":"2005","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0235","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1873-3468.14955","article-title":"The ATP-bound inward-open conformation of ABCC4 reveals asymmetric ATP binding for substrate transport","volume":"598","author":"Zhu","year":"2024","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tplants.2008.02.001","article-title":"Plant ABC proteins\u2013a unified nomenclature and updated inventory","volume":"13","author":"Verrier","year":"2008","journal-title":"Trends Plant Sci."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0245","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bcp.2026.117741_b0250","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.str.2023.08.014","article-title":"Structural and mechanistic basis of substrate transport by the multidrug transporter MRP4","volume":"31","author":"Bloch","year":"2023","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0255","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s42003-023-04935-7","article-title":"Structural basis for substrate and inhibitor recognition of human multidrug transporter MRP4","volume":"6","author":"Huang","year":"2023","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0260","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.20831","article-title":"Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma","volume":"115","author":"Konig","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003088-200746060-00001","article-title":"Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy","volume":"46","author":"Kock","year":"2007","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0270","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuroscience.2004.07.051","article-title":"Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain","volume":"129","author":"Nies","year":"2004","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0275","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2003.50331","article-title":"Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane","volume":"38","author":"Rius","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2026.117741_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.04.018","article-title":"Drugs and hepatic transporters: a review","volume":"154","author":"Jetter","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0285","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.V133595","article-title":"The MRP4\/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP","volume":"13","author":"van Aubel","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0290","first-page":"973","article-title":"A new blood corpuscle: an impossible interview with Giulio Bizzozero","volume":"86","author":"de Gaetano","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"21","key":"10.1016\/j.bcp.2026.117741_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112772","article-title":"Platelets and their role in hemostasis and thrombosis-from physiology to pathophysiology and therapeutic implications","volume":"23","author":"Scridon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0300","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0305","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","article-title":"Platelet alpha-granules: basic biology and clinical correlates","volume":"23","author":"Blair","year":"2009","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0310","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/MOH.0b013e3283632e6b","article-title":"Advances in platelet granule biology","volume":"20","author":"Koseoglu","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcp.2026.117741_b0315","doi-asserted-by":"crossref","first-page":"236","DOI":"10.12688\/f1000research.13283.1","article-title":"The life cycle of platelet granules","volume":"7","author":"Sharda","year":"2018","journal-title":"F1000Res"},{"issue":"11","key":"10.1016\/j.bcp.2026.117741_b0320","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood.V89.11.4047","article-title":"Platelet and megakaryocyte dense granules contain glycoproteins Ib and IIb-IIIa","volume":"89","author":"Youssefian","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0325","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/09537104.2016.1243789","article-title":"Storage pool diseases illuminate platelet dense granule biogenesis","volume":"28","author":"Ambrosio","year":"2017","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0330","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11302-011-9247-6","article-title":"P2 receptors and platelet function","volume":"7","author":"Hechler","year":"2011","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.bcp.2026.117741_b0335","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/204698b0","article-title":"Inhibition of adp-induced platelet aggregation by substituted amino-acids","volume":"204","author":"Salzman","year":"1964","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0340","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2353\/ajpath.2010.090425","article-title":"Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies","volume":"176","author":"Jedlitschky","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1538-7836.2011.04576.x","article-title":"Novel roles of cAMP\/cGMP-dependent signaling in platelets","volume":"10","author":"Smolenski","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0350","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1476-5381.1987.tb11310.x","article-title":"Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets","volume":"92","author":"Radomski","year":"1987","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0355","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1538-7836.2008.03014.x","article-title":"NO-synthase-\/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity","volume":"6","author":"Gambaryan","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0360","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0365","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1096\/fj.11-194027","article-title":"Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes","volume":"26","author":"Sassi","year":"2012","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0370","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1172\/JCI35067","article-title":"Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation","volume":"118","author":"Sassi","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0375","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1160\/TH12-04-0232","article-title":"Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport","volume":"108","author":"Borgognone","year":"2012","journal-title":"Thromb. Haemost."},{"issue":"20","key":"10.1016\/j.bcp.2026.117741_b0380","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2014-08-595942","article-title":"The ABCC4 membrane transporter modulates platelet aggregation","volume":"126","author":"Cheepala","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0385","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2003-12-4330","article-title":"The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage","volume":"104","author":"Jedlitschky","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2026.117741_b0390","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/ijc.24207","article-title":"Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs","volume":"124","author":"Oevermann","year":"2009","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.bcp.2026.117741_b0395","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2015-02-631044","article-title":"Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice","volume":"126","author":"Decouture","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0400","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood.V14.2.162.162","article-title":"Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies","volume":"14","author":"Hermansky","year":"1959","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0405","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.3324\/haematol.2021.279761","article-title":"Specific inhibition of the transporter MRP4\/ABCC4 affects multiple signaling pathways and thrombus formation in human platelets","volume":"107","author":"Wolf","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.117741_b0410","first-page":"25","article-title":"Biological effects of lysophospholipids","volume":"160","author":"Rivera","year":"2008","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0415","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1160\/TH17-04-0291","article-title":"Release of platelet-derived sphingosine-1-phosphate involves multidrug resistance protein 4 (MRP4\/ABCC4) and is inhibited by statins","volume":"118","author":"Vogt;","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0420","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1055\/s-0038-1641754","article-title":"Evidence that MRP4 is only partly involved in S1P secretion during platelet activation","volume":"118","author":"Decouture","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0425","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/jpet.107.131342","article-title":"ATP-dependent transport of leukotrienes B4 and C4 by the multidrug resistance protein ABCC4 (MRP4)","volume":"324","author":"Rius","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"18","key":"10.1016\/j.bcp.2026.117741_b0430","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1046\/j.1432-1033.2003.03753.x","article-title":"cGMP and glutathione-conjugate transport in human erythrocytes","volume":"270","author":"Klokouzas","year":"2003","journal-title":"Eur. J. Biochem."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0435","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bcp.2005.05.022","article-title":"Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes","volume":"70","author":"Wu","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0440","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood.2019002320","article-title":"Lack of the multidrug transporter MRP4\/ABCC4 defines the PEL-negative blood group and impairs platelet aggregation","volume":"135","author":"Azouzi","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0445","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2018-11-882993","article-title":"Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms","volume":"133","author":"Jackson","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0450","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/09537104.2020.1817360","article-title":"Immunothrombosis and thromboinflammation in host defense and disease","volume":"32","author":"Martinod","year":"2021","journal-title":"Platelets"},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0455","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1720553115","article-title":"Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration","volume":"115","author":"Cloutier","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0460","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2024.2413713","article-title":"Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents","volume":"35","author":"Tolksdorf","year":"2024","journal-title":"Platelets"},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0465","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0041-1726096","article-title":"Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives","volume":"47","author":"Christiansen","year":"2021","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0470","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jps.2600610312","article-title":"Absorption kinetics of aspirin in man following oral administration of an aqueous solution","volume":"61","author":"Rowland","year":"1972","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0475","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","article-title":"Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention","volume":"36","author":"Ornelas","year":"2017","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0480","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2165\/00003088-198510020-00004","article-title":"Clinical pharmacokinetics of the salicylates","volume":"10","author":"Needs","year":"1985","journal-title":"Clin. Pharmacokinet."},{"issue":"25","key":"10.1016\/j.bcp.2026.117741_b0485","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat. New Biol."},{"issue":"7415","key":"10.1016\/j.bcp.2026.117741_b0490","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.327.7415.572","article-title":"What are all the things that aspirin does?","volume":"327","author":"Flower","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0495","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat. Struct. Biol."},{"issue":"20","key":"10.1016\/j.bcp.2026.117741_b0500","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.116.023164","article-title":"Aspirin for primary cardiovascular risk prevention and beyond in diabetes mellitus","volume":"134","author":"Capodanno","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0505","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-020-00443-w","article-title":"Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"23","key":"10.1016\/j.bcp.2026.117741_b0510","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239020","article-title":"Effect of prostanoids on human platelet function: an overview","volume":"21","author":"Braune","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0515","first-page":"95","article-title":"Acetylsalicylic acid, possible preventive of coronary thrombosis","volume":"4","author":"Craven","year":"1950","journal-title":"Ann. West. Med. Surg."},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0520","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.4983","article-title":"Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement","volume":"327","author":"Force","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.117741_b0525","article-title":"Effect of frequently prescribed drugs on gastric cancer risk","volume":"50\u201351","author":"Weltermann","year":"2021","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0530","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02649.x","article-title":"Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin","volume":"22","author":"Yeomans","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6983","key":"10.1016\/j.bcp.2026.117741_b0535","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0540","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1172\/JCI108941","article-title":"Inhibition of platelet prostaglandin synthetase by oral aspirin","volume":"61","author":"Burch","year":"1978","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0049-3848(82)90283-3","article-title":"Dosage frequency for suppression of platelet function by low dose aspirin therapy","volume":"27","author":"Bradlow","year":"1982","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0550","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","article-title":"Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis","volume":"23","author":"Schror","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0555","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low-dose aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0560","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action","volume":"12","author":"Patrignani","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"1 Suppl","key":"10.1016\/j.bcp.2026.117741_b0565","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs : the relationships among dose, effectiveness, and side effects","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"issue":"9678","key":"10.1016\/j.bcp.2026.117741_b0570","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0575","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0580","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1538-7836.2005.01351.x","article-title":"Aspirin resistance: position paper of the Working Group on Aspirin Resistance","volume":"3","author":"Michelson","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0585","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","article-title":"Aspirin resistance: definition, mechanisms and clinical read-outs","volume":"1","author":"Patrono","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0590","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jacc.2003.08.062","article-title":"Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients","volume":"43","author":"Pulcinelli","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0595","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","article-title":"Mechanisms of aspirin resistance","volume":"141","author":"Floyd","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0600","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jacc.2011.04.025","article-title":"Overexpression of the multidrug resistance protein-4 transporter in patients undergoing coronary artery bypass graft surgery a cause of aspirin resistance?","volume":"58","author":"Eikelboom","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0605","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0610","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","article-title":"Aspirin resistance and atherothrombotic disease","volume":"46","author":"Mason","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0615","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","volume":"30","author":"Kuliczkowski","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.117741_b0620","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1479-5876-6-46","article-title":"Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients","volume":"6","author":"Schwartz","year":"2008","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.117741_b0625","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"Wurtz","year":"2010","journal-title":"Heart"},{"issue":"8022","key":"10.1016\/j.bcp.2026.117741_b0630","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Franca","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0635","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11239-017-1516-y","article-title":"Platelet-related biomarkers and their response to inhibition with aspirin and p2y(12)-receptor antagonists in patients with acute coronary syndrome","volume":"44","author":"Lowenstern","year":"2017","journal-title":"J. Thromb. Thrombolysis"},{"issue":"14","key":"10.1016\/j.bcp.2026.117741_b0640","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacc.2013.05.073","article-title":"Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events","volume":"62","author":"Voora","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0645","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cvr\/cvac079","article-title":"An antiplatelet response gene expression signature is associated with bleeding","volume":"119","author":"Friede","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0650","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1111\/j.1538-7836.2005.01633.x","article-title":"Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin","volume":"3","author":"Pulcinelli","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0655","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","article-title":"Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib","volume":"19","author":"Furmanski","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0660","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/03602532.2017.1293682","article-title":"Glucuronidation: driving factors and their impact on glucuronide disposition","volume":"49","author":"Yang","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bcp.2026.117741_b0665","article-title":"The Role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates","volume":"12","author":"Jarvinen","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0670","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s44161-023-00289-9","article-title":"Structural insights into human ABCC4-mediated transport of platelet agonist and antagonist","volume":"2","author":"Chen","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0675","doi-asserted-by":"crossref","DOI":"10.3390\/biom14020231","article-title":"structural view of cryo-electron microscopy-determined ATP-binding cassette transporters in human multidrug resistance","volume":"14","author":"Fan","year":"2024","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0680","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1160\/TH16-04-0316","article-title":"Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment","volume":"116","author":"Massimi","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.117741_b0685","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3389\/fimmu.2017.01946","article-title":"From human megakaryocytes to platelets: effects of aspirin on high-mobility group box 1\/receptor for advanced glycation end products axis","volume":"8","author":"Mardente","year":"2017","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0690","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2010-12-324517","article-title":"Megakaryocytes differentially sort mRNAs for matrix metalloproteinases and their inhibitors into platelets: a mechanism for regulating synthetic events","volume":"118","author":"Cecchetti","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0695","doi-asserted-by":"crossref","first-page":"12358","DOI":"10.1038\/s41598-021-91661-x","article-title":"Assessment of a complete and classified platelet proteome from genome-wide transcripts of human platelets and megakaryocytes covering platelet functions","volume":"11","author":"Huang","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0700","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/bcp.12432","article-title":"Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets","volume":"78","author":"Massimi","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0705","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/rth2.12104","article-title":"MiR-21 role in aspirin-dependent PPARalpha and multidrug resistance protein 4 upregulation","volume":"2","author":"Massimi","year":"2018","journal-title":"Res Pract Thromb Haemost."},{"issue":"23","key":"10.1016\/j.bcp.2026.117741_b0710","first-page":"8487","article-title":"Non-steroidal anti-inflammatory drugs increase MRP4 expression in an endometriotic epithelial cell line in a PPARa dependent manner","volume":"22","author":"Massimi","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2026.117741_b0715","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1749-6632.1993.tb32279.x","article-title":"Peroxisome proliferator-activated receptors and lipid metabolism","volume":"684","author":"Keller","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062061","article-title":"PPARs as Metabolic regulators in the Liver: Lessons from Liver-specific PPAR-Null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.117741_b0725","first-page":"101","article-title":"PPAR: a mediator of peroxisome proliferator action","volume":"333","author":"Green","year":"1995","journal-title":"Mutat. Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0730","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5551\/jat.5868","article-title":"Activation of peroxisome proliferator-activated receptor alpha in megakaryocytes reduces platelet-derived growth factor-BB in platelets","volume":"18","author":"Hashizume","year":"2011","journal-title":"J. Atheroscler. Thromb."},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0735","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/0092-8674(89)90051-2","article-title":"Determinants of target gene specificity for steroid\/thyroid hormone receptors","volume":"57","author":"Umesono","year":"1989","journal-title":"Cell"},{"issue":"6212","key":"10.1016\/j.bcp.2026.117741_b0740","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/338271a0","article-title":"Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element","volume":"338","author":"Mader","year":"1989","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0745","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.biopha.2009.04.033","article-title":"Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha\/gamma and COX-2\/mPGES-1-mediated pathways in macrophages derived from THP-1 cells","volume":"64","author":"Xue","year":"2010","journal-title":"Biomed. Pharmacother."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2026.117741_b0750","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000321727","article-title":"Aspirin increases apolipoprotein-A-I-mediated cholesterol efflux via enhancing expression of ATP-binding cassette transporter A1","volume":"86","author":"Wang","year":"2010","journal-title":"Pharmacology"},{"issue":"30","key":"10.1016\/j.bcp.2026.117741_b0755","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1523\/JNEUROSCI.0054-18.2018","article-title":"Aspirin induces lysosomal biogenesis and attenuates amyloid plaque pathology in a mouse model of alzheimer's disease via PPARalpha","volume":"38","author":"Chandra","year":"2018","journal-title":"J. Neurosci."},{"issue":"16","key":"10.1016\/j.bcp.2026.117741_b0760","doi-asserted-by":"crossref","first-page":"10309","DOI":"10.1074\/jbc.M114.610659","article-title":"Activation of peroxisome proliferator-activated receptor alpha induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders","volume":"290","author":"Ghosh","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"31","key":"10.1016\/j.bcp.2026.117741_b0765","doi-asserted-by":"crossref","first-page":"E7408","DOI":"10.1073\/pnas.1802021115","article-title":"Aspirin binds to PPARalpha to stimulate hippocampal plasticity and protect memory","volume":"115","author":"Patel","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0770","first-page":"519","article-title":"Genome-wide identification of TCF7L2\/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer","volume":"40","author":"Lan","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2026.117741_b0775","article-title":"Circulating MRP8\/14 drives faster platelet COX-1 recovery via MRP4 impairing the duration of aspirin response","author":"Liani","year":"2025","journal-title":"Blood Adv."},{"issue":"17","key":"10.1016\/j.bcp.2026.117741_b0780","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"issue":"23 Pt A","key":"10.1016\/j.bcp.2026.117741_b0785","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison","volume":"72","author":"Capodanno","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.117741_b0790","first-page":"e24","article-title":"Monitoring antiplatelet therapy: where are we now?","volume":"24","author":"Marcucci","year":"2023","journal-title":"J. Cardiovasc. Med. (Hagerstown)"},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0795","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2014.06.1157","article-title":"Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing?","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0800","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ijcard.2007.12.010","article-title":"Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events\u2013a meta-analysis","volume":"128","author":"Sofi","year":"2008","journal-title":"Int. J. Cardiol."},{"issue":"7637","key":"10.1016\/j.bcp.2026.117741_b0805","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.bcp.2026.117741_b0810","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2017.03.010","article-title":"High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: a systematic review and meta-analysis","volume":"376","author":"Fiolaki","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0815","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","article-title":"Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI Registry","volume":"64","author":"Mayer","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0820","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/jama.1983.03340090057031","article-title":"The relation of blood platelets to hemorrhagic disease. by W.W. Duke","volume":"250","author":"Duke","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2026.117741_b0825","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.117741_b0830","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0835","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0049-3848(84)90372-4","article-title":"An assessment of whole blood impedance aggregometry using blood from normal subjects and haemodialysis patients","volume":"36","author":"Gordge","year":"1984","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcp.2026.117741_b0840","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/ISTH","volume":"11","author":"Cattaneo","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"25","key":"10.1016\/j.bcp.2026.117741_b0845","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/01.CIR.103.25.3051","article-title":"Genetic and environmental contributions to platelet aggregation: the Framingham heart study","volume":"103","author":"O'Donnell","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0850","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol. Sex Differ."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.117741_b0855","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(81)90233-4","article-title":"Sex differences in the platelet response to aspirin","volume":"23","author":"Coppe","year":"1981","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0860","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00560385","article-title":"The influence of age on the activity of acetylsalicylic acid-esterase and protein-salicylate binding","volume":"7","author":"Windorfer","year":"1974","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0865","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/cpt1977224410","article-title":"Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis","volume":"22","author":"Graham","year":"1977","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0870","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11239-024-03022-w","article-title":"Interindividual variability in platelet reactivity among individuals with or without antiplatelet therapy: results from a large tertiary care hospital","volume":"58","author":"Galli","year":"2025","journal-title":"J. Thromb. Thrombolysis"},{"issue":"10283","key":"10.1016\/j.bcp.2026.117741_b0875","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.bcp.2026.117741_b0880","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/07853890.2011.605388","article-title":"A contemporary viewpoint on 'aspirin resistance'","volume":"44","author":"Kuzniatsova","year":"2012","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0885","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1055\/s-0038-1629920","article-title":"Impact of multidrug resistance protein-4 inhibitors on modulating platelet function and high on-aspirin treatment platelet reactivity","volume":"118","author":"Alemanno","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0890","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14656566.2019.1707181","article-title":"The use of cilostazol for secondary stroke prevention: isn't time to be evaluated in Western countries?","volume":"21","author":"Di Napoli","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0895","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.amjcard.2017.11.005","volume":"121","author":"Lee","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"21","key":"10.1016\/j.bcp.2026.117741_b0900","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2026.117741_b0905","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11239-020-02214-4","article-title":"MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation","volume":"51","author":"Guarino","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"issue":"11","key":"10.1016\/j.bcp.2026.117741_b0910","first-page":"869","article-title":"Dipyridamole: a critical evaluation","volume":"18","author":"Rivey","year":"1984","journal-title":"Drug Intell. Clin. Pharm."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0915","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/STROKEAHA.107.496281","article-title":"Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis","volume":"39","author":"Verro","year":"2008","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0920","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/01.STR.14.1.5","article-title":"\u201cAICLA\u201d controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia","volume":"14","author":"Bousser","year":"1983","journal-title":"Stroke"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2026.117741_b0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0930","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.STR.0000149621.95215.ea","article-title":"Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials","volume":"36","author":"Leonardi-Bee","year":"2005","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.bcp.2026.117741_b0935","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the american heart association\/american stroke association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0940","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s11095-005-8384-4","article-title":"BCRP transports dipyridamole and is inhibited by calcium channel blockers","volume":"22","author":"Zhang","year":"2005","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.bcp.2026.117741_b0945","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside transporter proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117741_b0950","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/dmd.115.066654","article-title":"Local drug-drug interaction of donepezil with cilostazol at breast cancer resistance protein (ABCG2) increases drug accumulation in heart","volume":"44","author":"Takeuchi","year":"2016","journal-title":"Drug Metab. Dispos."},{"issue":"9523","key":"10.1016\/j.bcp.2026.117741_b0955","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"Group ES","year":"2006","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0960","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0965","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(00)01135-9","article-title":"Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis","volume":"37","author":"Massel","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117741_b0970","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.117741_b0975","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: a Study in long-term Effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J. Vasc. Surg."},{"issue":"12","key":"10.1016\/j.bcp.2026.117741_b0980","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117741_b0985","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.07.010","article-title":"Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials","volume":"18","author":"Uchiyama","year":"2009","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.bcp.2026.117741_b0990","article-title":"Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: a randomized controlled multi-center trial, the TACTIS trial","volume":"17474930251406865","author":"Ismaiel","year":"2025","journal-title":"Int. J. Stroke"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226000729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:41:46Z","timestamp":1778056906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226000729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":198,"alternative-id":["S0006295226000729"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117741","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting MRP4 in drug resistance and aspirin treatment failure: implications for precision medicine","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117741"}}